The Extracellular Niche and Tumor Microenvironment Enhance KRAS Inhibitor Efficacy in Pancreatic Cancer
Vishnu Kumarasamy(Roswell Park Comprehensive Cancer Center), Agnieszka K. Witkiewicz(Roswell Park Comprehensive Cancer Center)
Cited by 45
Related Papers
Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets
|Nature Communications|2015|1.1k
p27 allosterically activates cyclin-dependent kinase 4 and antagonizes palbociclib inhibition
|Science|2019|238
Selective repression of RET proto-oncogene in medullary thyroid carcinoma by a natural alkaloid berberine
|BMC Cancer|2015|36
Discrete vulnerability to pharmacological CDK2 inhibition is governed by heterogeneity of the cancer cell cycle
|Nature Communications|2025|28
Demonstration of a potent RET transcriptional inhibitor for the treatment of medullary thyroid carcinoma based on an ellipticine derivative
|International Journal of Oncology|2017|15